Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic Breast cancer

CAR-T Digest - August 2020

Weekly Digest - April 2025

21 Apr 2025: Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic Breast cancer

The DESTINY-Breast09 Phase 3 trial showed that Enhertu combined with Pertuzumab significantly improved progression-free survival compared to the current 1st-line standard of care of Taxane, Trastuzumab and Pertuzumab (THP) in patients with HER2-positive metastatic breast cancer
This is the first trial in over a decade to demonstrate superior efficacy across a broad HER2-positive patient population versus THP, marking a potential shift in 1st-line treatment standards
Progression-free survival benefits were consistent across all pre-specified patient subgroups, with interim overall survival data showing a favorable trend for the Enhertu combination
The second arm of the trial comparing Enhertu monotherapy to THP remains blinded and ongoing, and overall survival results are not yet mature
The safety profile of Enhertu plus Pertuzumab was consistent with known data, and detailed results will be presented at a future medical meeting and shared with regulatory authorities